Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Reaman

Showing results (41-50 of 83) with videos related to

Pageof 9
Sort By:
Pediatric Blood & Cancer|September 8, 2020
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patientsMargret Merino, Nicholas Richardson, Gregory Reaman, et al.
The Oncologist|May 29, 2020
Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019Vishal Bhatnagar, Stacie Hudgens, Elisabeth Piault-Louis, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Therapeutic Innovation & Regulatory Science|May 16, 2018
Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master ProtocolsTahira Khan, Mark Stewart, Samuel Blackman, et al.
Cancer Medicine|May 31, 2018
Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trialsLori M Minasian, A Lindsay Frazier, Lillian Sung, et al.
Archives of Internal Medicine|September 24, 2008
Signposts along the NIH roadmap for reengineering clinical research: lessons from the Clinical Research Networks initiativeRobert L Williams, Stephen B Johnson, Sarah M Greene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experienceAnne L Angiolillo, Virginia Davenport, Mary Ann Bonilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.
BMC Biology|December 24, 2010
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNAPhilipp Kapranov, Georges St Laurent, Tal Raz, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
Pageof 9

Showing results (41-50 of 83) with videos related to

Sort By:
Pageof 9
Pediatric Blood & Cancer|September 8, 2020
FDA approval summary: Dalteparin for the treatment of symptomatic venous thromboembolism in pediatric patientsMargret Merino, Nicholas Richardson, Gregory Reaman, et al.
The Oncologist|May 29, 2020
Patient-Reported Outcomes in Oncology Clinical Trials: Stakeholder Perspectives from the Accelerating Anticancer Agent Development and Validation Workshop 2019Vishal Bhatnagar, Stacie Hudgens, Elisabeth Piault-Louis, et al.
Pediatric Blood & Cancer|May 13, 2022
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphomaMargret Merino, Yvette Kasamon, Hongshan Li, et al.
Therapeutic Innovation & Regulatory Science|May 16, 2018
Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master ProtocolsTahira Khan, Mark Stewart, Samuel Blackman, et al.
Cancer Medicine|May 31, 2018
Prevention of cisplatin-induced hearing loss in children: Informing the design of future clinical trialsLori M Minasian, A Lindsay Frazier, Lillian Sung, et al.
Archives of Internal Medicine|September 24, 2008
Signposts along the NIH roadmap for reengineering clinical research: lessons from the Clinical Research Networks initiativeRobert L Williams, Stephen B Johnson, Sarah M Greene, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2005
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experienceAnne L Angiolillo, Virginia Davenport, Mary Ann Bonilla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 3, 2017
Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working GroupLia Gore, S Percy Ivy, Frank M Balis, et al.
BMC Biology|December 24, 2010
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNAPhilipp Kapranov, Georges St Laurent, Tal Raz, et al.
Neuro-Oncology|August 22, 2008
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I studyKristin A Bradley, Ian F Pollack, Joel M Reid, et al.
Pageof 9